Monitor for future patent grants in key markets and upcoming clinical trial data, especially for alcohol use disorder programs. This IP filing alone does not justify a valuation shift given lack of commercial-stage assets or revenue.
Price Chart
Executive Summary
Clearmind Medicine announced the filing of a patent application in India for next-generation, non-hallucinogenic psychedelic-based compounds targeting mental health and addiction disorders. This expands its global IP portfolio, which includes 31 granted patents across 19 families, supporting its strategy to develop scalable, safer therapeutics. The filing is a procedural IP development with no immediate financial impact.
Key Facts
- Filed patent application in India for novel, non-hallucinogenic psychedelic compounds
- Part of an expanding global IP portfolio with 31 granted patents across 19 families
- Compounds aim to improve upon limitations of classical psychedelics
- No financial terms, revenue impact, or clinical data disclosed
- Forward-looking statements emphasize uncertainty around patent issuance or commercial benefit
Financial Impact
No immediate financial impact; potential long-term IP value enhancement
Risk Factors
- Patent may not issue or could be granted in a narrower form than claimed
- No assurance of clinical or commercial success despite IP expansion
- Company remains pre-revenue with high development and regulatory risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263700 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G | $6.10 | awaiting T+60 | — | $5.97 (−2.10%) |
Oct 27, 2026 today | 6-K | $5.92 | awaiting T+60 | — | $5.97 (+0.79%) |
Oct 27, 2026 today | Press Release | $6.50 | awaiting T+60 | — | $5.97 (−8.20%) |
Oct 16, 2026 11d ago | 6-K | $6.00 | awaiting T+60 | — | $5.97 (+0.55%) |
Oct 13, 2026 14d ago | 6-K | $6.23 | awaiting T+60 | — | $5.97 (−4.22%) |
Oct 8, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Oct 7, 2026 20d ago | 6-K | $6.60 | awaiting T+60 | — | $5.97 (−9.59%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.97 (+602.00%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.97 (−13.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers